Matches in SemOpenAlex for { <https://semopenalex.org/work/W3048559940> ?p ?o ?g. }
- W3048559940 endingPage "200" @default.
- W3048559940 startingPage "192" @default.
- W3048559940 abstract "Cardiovascular disease is the leading cause of death worldwide. Conceptually, endothelial dysfunction, inflammatory conditions and oxidative stress are at the forefront of the onset and development of most cardiovascular diseases, particularly coronary artery disease and heart failure. Serum albumin has many physiological properties, including in particular antioxidant, anti-inflammatory, anticoagulant and anti-platelet aggregation activity. It also plays an essential role in the exchange of fluids across the capillary membrane. Hypoalbuminemia is a powerful prognostic marker in the general population as well as in many disease states. In the more specific context of cardiovascular disease, low serum albumin is independently associated with the development of various deleterious conditions such as coronary artery disease, heart failure, atrial fibrillation, stroke and venous thromboembolism. Low serum albumin has also emerged as a potent prognostic parameter in patients with cardiovascular disease regardless of usual prognostic markers. Remarkably, its potent prognostic value persists after adjusting for causative confounders such as malnutrition and inflammation. This prognostic value probably refers primarily to the syndrome of malnutrition-inflammation and the severity of comorbidities. Nevertheless, several recent meta-analyses strongly support the hypothesis that hypoalbuminemia may act as an unrecognized, potentially modifiable risk factor contributing to the emergence and progression of cardiovascular disease, primarily by exacerbating oxidative stress, inflammation and platelet aggregation, and by favouring peripheral congestion and pulmonary edema. Currently, it is unknown whether prevention and correction of low serum albumin offers a benefit to patients with or at risk for cardiovascular disease, and further studies are critically needed in this setting. Les maladies cardiovasculaires sont la principale cause de mortalité dans le monde. Sur un plan conceptuel, la dysfonction endothéliale, l’inflammation et le stress oxydatif sont impliqués dans l’émergence et l’aggravation de la plupart des maladies cardiovasculaires, en particulier l’insuffisance coronaire et l’insuffisance cardiaque. L’albumine sérique a de nombreuses propriétés physiologiques en particulier une action anti-oxydante, anti-inflammatoire, anticoagulante et anti-aggrégante. Elle joue aussi un rôle essentiel dans les échanges liquidiens transmembranaires. L’hypo-albuminémie est un puissant marqueur pronostique dans la population générale et dans de nombreuses pathologies. Dans le contexte des maladies cardiovasculaires, l’hypo-albuminémie est indépendamment associée à l’émergence de nombreuses maladies cardiovasculaires, comme l’insuffisance coronaire, l’insuffisance cardiaque, les AVC, la fibrillation atriale et la maladie thrombo-embolique veineuse. Elle offre aussi une information pronostique indépendante dans la plupart des maladies cardiovasculaires. De manière remarquable, cette valeur pronostique persiste après ajustement de la dénutrition et de l’inflammation. Cette valeur pronostique est probablement liée en premier lieu au syndrome de dénutrition-inflammation et à la sévérité des comorbidités. Néanmoins, plusieurs méta-analyses récentes suggèrent que l’hypo-albuminémie pourrait être un facteur de risque méconnu dans l’émergence et l’aggravation de maladies cardiovasculaires, principalement par exacerbation de l’inflammation et du stress oxydatif, la congestion périphérique et l’œdème pulmonaire. Actuellement, aucune étude n’a évalué l’impact pronostique de la prévention ou de la correction de l’hypo-albuminémie dans les maladies cardiovasculaires et des études cliniques sont nécessaires dans ce contexte." @default.
- W3048559940 created "2020-08-18" @default.
- W3048559940 creator A5072853827 @default.
- W3048559940 date "2020-10-01" @default.
- W3048559940 modified "2023-10-16" @default.
- W3048559940 title "Serum albumin and cardiovascular disease: State-of-the-art review" @default.
- W3048559940 cites W1170694745 @default.
- W3048559940 cites W1493640535 @default.
- W3048559940 cites W1885775271 @default.
- W3048559940 cites W1900043612 @default.
- W3048559940 cites W1970463993 @default.
- W3048559940 cites W1970658172 @default.
- W3048559940 cites W1975123647 @default.
- W3048559940 cites W1976792130 @default.
- W3048559940 cites W1978017467 @default.
- W3048559940 cites W1978131174 @default.
- W3048559940 cites W1978868043 @default.
- W3048559940 cites W1981959070 @default.
- W3048559940 cites W1981981160 @default.
- W3048559940 cites W1982631606 @default.
- W3048559940 cites W1983330058 @default.
- W3048559940 cites W1983338129 @default.
- W3048559940 cites W1985229426 @default.
- W3048559940 cites W1987821085 @default.
- W3048559940 cites W1995638306 @default.
- W3048559940 cites W1997701104 @default.
- W3048559940 cites W2001220717 @default.
- W3048559940 cites W2003791195 @default.
- W3048559940 cites W2005528206 @default.
- W3048559940 cites W2007496527 @default.
- W3048559940 cites W2007790334 @default.
- W3048559940 cites W2017463574 @default.
- W3048559940 cites W2029014150 @default.
- W3048559940 cites W2029082818 @default.
- W3048559940 cites W2029672419 @default.
- W3048559940 cites W2035446068 @default.
- W3048559940 cites W2036736228 @default.
- W3048559940 cites W2043336768 @default.
- W3048559940 cites W2045805549 @default.
- W3048559940 cites W2049209813 @default.
- W3048559940 cites W2055534323 @default.
- W3048559940 cites W2060160690 @default.
- W3048559940 cites W2062743399 @default.
- W3048559940 cites W2068489677 @default.
- W3048559940 cites W2071098445 @default.
- W3048559940 cites W2087006763 @default.
- W3048559940 cites W2089134874 @default.
- W3048559940 cites W2095921420 @default.
- W3048559940 cites W2107322156 @default.
- W3048559940 cites W2114659478 @default.
- W3048559940 cites W2117584553 @default.
- W3048559940 cites W2119221698 @default.
- W3048559940 cites W2120098674 @default.
- W3048559940 cites W2125846571 @default.
- W3048559940 cites W2130030337 @default.
- W3048559940 cites W2135002706 @default.
- W3048559940 cites W2140347742 @default.
- W3048559940 cites W2156897241 @default.
- W3048559940 cites W2157703222 @default.
- W3048559940 cites W2160505054 @default.
- W3048559940 cites W2160641484 @default.
- W3048559940 cites W2161935483 @default.
- W3048559940 cites W2168663672 @default.
- W3048559940 cites W2288345372 @default.
- W3048559940 cites W2339432002 @default.
- W3048559940 cites W2343605353 @default.
- W3048559940 cites W2377217515 @default.
- W3048559940 cites W2392200964 @default.
- W3048559940 cites W2397322854 @default.
- W3048559940 cites W2414251448 @default.
- W3048559940 cites W2428503107 @default.
- W3048559940 cites W2460078740 @default.
- W3048559940 cites W2491188335 @default.
- W3048559940 cites W2507726653 @default.
- W3048559940 cites W2535351664 @default.
- W3048559940 cites W2548326080 @default.
- W3048559940 cites W2569251764 @default.
- W3048559940 cites W2573076882 @default.
- W3048559940 cites W2593271198 @default.
- W3048559940 cites W2594513543 @default.
- W3048559940 cites W2600746219 @default.
- W3048559940 cites W2605027965 @default.
- W3048559940 cites W2607242643 @default.
- W3048559940 cites W2613855532 @default.
- W3048559940 cites W2623867926 @default.
- W3048559940 cites W2626156940 @default.
- W3048559940 cites W2740191821 @default.
- W3048559940 cites W2744355055 @default.
- W3048559940 cites W2752353493 @default.
- W3048559940 cites W2763516672 @default.
- W3048559940 cites W2770914153 @default.
- W3048559940 cites W2793160687 @default.
- W3048559940 cites W2793438810 @default.
- W3048559940 cites W2795232490 @default.
- W3048559940 cites W2908610946 @default.
- W3048559940 cites W2910337510 @default.
- W3048559940 cites W2964481763 @default.
- W3048559940 cites W2967381667 @default.